Lucid Diagnostics Recognized as a GenomeWeb Best Place to Work for Second Consecutive Year

(NASDAQ:LUCD) Lucid Diagnostics Inc., a commercial-stage cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (NASDAQ:PAVM), announced it has been named a GenomeWeb 2026 Best Places to Work honoree. This marks the second consecutive year that Lucid Diagnostics has received this recognition in GenomeWeb's annual program, which highlights top workplaces in the life sciences research, diagnostics, and precision medicine sectors. Shaun O'Neil, President and Chief Operating Officer of Lucid Diagnostics, stated that the award is especially meaningful as it is based on direct feedback from team members and reflects the company's culture of collaboration, mutual respect, and commitment to excellence. O'Neil also noted that with EsoGuard now fully reimbursed by Medicare nationwide, the company's culture will support team expansion and accelerated commercialization. GenomeWeb's Best Places to Work program evaluates companies based on employee feedback surveys, which account for 80% of the overall score, and an assessment of workplace policies and practices, which accounts for the remaining 20%. Lucid Diagnostics focuses on patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, who are at risk of developing esophageal precancer and cancer. The company's EsoGuard Esophageal DNA Test, performed on samples collected using the EsoCheck Esophageal Cell Collection Device, is described as the first and only commercially available tool designed to prevent cancer and cancer deaths through widespread, early detection of esophageal precancer in at-risk patients. Lucid Diagnostics is a subsidiary of PAVmed Inc. GenomeWeb is an independent online news organization that has served the global community of scientists, technology professionals, and executives in molecular biology research and diagnostics since 1997. GenomeWeb's audience includes biopharmaceutical companies, research universities, biomedical institutes, clinical laboratories, and government organizations. The recognition by GenomeWeb is based on both employee feedback and company workplace policies. Lucid Diagnostics emphasizes its commitment to preventing esophageal cancer and supporting professional development within its team. The company highlights the importance of Medicare reimbursement for EsoGuard in its commercialization strategy. Lucid Diagnostics' products are designed for early detection and prevention of esophageal cancer in patients with GERD. The company has now been recognized by GenomeWeb for two consecutive years. The annual GenomeWeb program is a significant industry honor in the life sciences sector.

Lucid Diagnostics Announces Publication of Landmark 12,000-Patient Real-World EsoGuard® Study

(NASDAQ:LUCD) Lucid Diagnostics Inc., a commercial-stage cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (NASDAQ:PAVM), announced the peer-reviewed publication of findings from the largest real-world clinical experience of nonendoscopic esophageal precancer testing to date. The study, titled "Non-Endoscopic Screening for Barrett's Esophagus Using a DNA Methylation-Based Assay: Real-World Experience in 11,991 Patients," was published in the journal Diagnostics. The study included 11,991 patients with clinical risk factors who underwent EsoGuard testing on samples collected with the EsoCheck Esophageal Cell Collection Device between January 2023 and June 2024. Cell collection was successful in 95% of patients, with an average collection time of less than two minutes and no reported device-related adverse events. In a post-procedure survey, 82% of patients reported very low discomfort, and only 0.2% rated their discomfort as high. 96% of patients said they would recommend the test to others, and 95% said they would undergo the test again if clinically indicated. The study found that EsoCheck cell collection was rapid, well tolerated, and consistent across operators, including newly trained personnel. Lishan Aklog, M.D., Lucid's Chairman and Chief Executive Officer, stated that these findings provide compelling real-world evidence supporting the feasibility of large-scale implementation of EsoGuard testing, especially as EsoGuard is now fully reimbursed by Medicare nationwide. Victoria T. Lee, M.D., Lucid's Chief Medical Officer, commented that the high cell collection success rate, high patient satisfaction scores, and short average procedure time strongly support large-scale implementation to expand access to esophageal precancer testing in at-risk patients.

Lucid Diagnostics Secures Commercial Coverage Policy Spanning Multiple Health Plans for its EsoGuard® Esophageal DNA Test

(NASDAQ: LUCD) Lucid Diagnostics Inc. announced that Concert, a healthcare technology company recently acquired by Lyric, issued a positive coverage policy effective July 2026 for non-invasive screening of esophageal precancer and cancer. The policy recognizes EsoGuard ® as the only esophageal precancer test meeting its coverage criteria and considers Lucid's EsoGuard ® Esophageal DNA Test medically necessary in patients who meet American College of Gastroenterology (ACG) screening criteria. Multiple Concert client health plans have already adopted this coverage policy. Lucid Diagnostics Inc. is a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (NASDAQ: PAVM). Lucid is focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, who are at risk of developing esophageal precancer and cancer. The company projects that securing this coverage policy is another significant step toward broad commercial coverage of EsoGuard. Lucid's EsoGuard ® Esophageal DNA Test and EsoCheck ® Esophageal Cell Collection Device represent the first and only commercially available tools designed with the goal of preventing cancer and cancer deaths through widespread, early detection of esophageal precancer in at-risk patients.

Lucid Diagnostics Announces Closing of $18 Million Underwritten Offering of Common Stock

Lucid Diagnostics Inc. (NASDAQ:LUCD), a commercial-stage cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (NASDAQ:PAVM), announced the closing of its previously announced underwritten registered direct offering of 18,000,000 common shares at a purchase price of $1.00 per share. The offering was anchored by a $15 million investment from a fundamental institutional investor with support from a large existing shareholder. Gross proceeds from the offering were approximately $18 million before deducting underwriting discounts, commissions, and other estimated offering expenses. The company intends to use the net proceeds for working capital and general corporate purposes. Canaccord Genuity LLC and BTIG, LLC acted as joint bookrunners for the offering.

Lucid Diagnostics Announces $18 Million Underwritten Offering of Common Stock

Lucid Diagnostics Inc. (Nasdaq: LUCD), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), announced the pricing of an underwritten registered direct. The announcement was made in New York on April 23, 2026. The company is listed on Nasdaq under the ticker LUCD. This announcement is significant for investors as it relates to the company's capital raising activities.